These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21536094)

  • 1. The emergence of designed multiple ligands for neurodegenerative disorders.
    Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
    Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal drugs and their future for Alzheimer's and Parkinson's disease.
    Van der Schyf CJ; Geldenhuys WJ
    Int Rev Neurobiol; 2011; 100():107-25. PubMed ID: 21971005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
    Waldmeier P; Bozyczko-Coyne D; Williams M; Vaught JL
    Biochem Pharmacol; 2006 Nov; 72(10):1197-206. PubMed ID: 16901468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.
    Geldenhuys WJ; Van der Schyf CJ
    Expert Opin Drug Discov; 2013 Feb; 8(2):115-29. PubMed ID: 23231597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.
    Youdim MB; Buccafusco JJ
    Trends Pharmacol Sci; 2005 Jan; 26(1):27-35. PubMed ID: 15629202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.
    Wang Q; Yan J; Chen X; Li J; Yang Y; Weng J; Deng C; Yenari MA
    Exp Neurol; 2011 Jul; 230(1):27-34. PubMed ID: 20406638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.
    Liu T; Bitan G
    ChemMedChem; 2012 Mar; 7(3):359-74. PubMed ID: 22323134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
    Chen JF; Chern Y
    Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is good old minocycline a new neuroprotective drug?].
    Melero-Fernández de Mera RM; García-Martínez E; Fernández-Gómez FJ; Hernández-Guijo JM; Aguirre N; Galindo MF; Jordán J
    Rev Neurol; 2008 Jul 1-15; 47(1):31-8. PubMed ID: 18592478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V; Herrling P
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract]   [Full Text] [Related]  

  • 12. Fluorinated molecules in the diagnosis and treatment of neurodegenerative diseases.
    Gaye B; Adejare A
    Future Med Chem; 2009 Aug; 1(5):821-33. PubMed ID: 21426082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's in the pipeline for the treatment of Parkinson's disease?
    Sommer DB; Stacy MA
    Expert Rev Neurother; 2008 Dec; 8(12):1829-39. PubMed ID: 19086879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO; Herrling P
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment possibilities of Alzheimer's disease.
    Miklya I; Gaszner P
    Neuropsychopharmacol Hung; 2004 Dec; 6(4):200-9. PubMed ID: 15825676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The brain as a target for inflammatory processes and neuroprotective strategies.
    Skaper SD
    Ann N Y Acad Sci; 2007 Dec; 1122():23-34. PubMed ID: 18077562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases.
    Mandel SA; Amit T; Weinreb O; Youdim MB
    J Alzheimers Dis; 2011; 25(2):187-208. PubMed ID: 21368374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
    Miklya I
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.